Trientine: Clinical Guidelines, Dosage, and Pharmacology
Trientine is a highly selective chelating agent, specifically a polyamine (triethylenetetramine dihydrochloride), designed for the pathogenetic treatment of Wilson-Konovalov disease (hepatolenticular degeneration). The drug was developed as a life-saving alternative to D-penicillamine for patients in whom first-line therapy causes severe side effects or proves ineffective.
The mechanism of action involves the formation of stable, soluble complexes (chelates) with copper ions (Cu2+) in the blood and tissues. These complexes are readily filtered by the kidneys and excreted from the body via urine (cupriuria). Unlike penicillamine, trientine has a different chemical structure (it does not contain sulfhydryl groups), which reduces the risk of many immune-complex-mediated side reactions.
The medication effectively reduces systemic copper toxicity, preventing its accumulation in hepatocytes and the basal ganglia of the brain, which helps alleviate neurological symptoms and prevents the development of liver cirrhosis and fulminant hepatic failure.
Indications
Trientine is indicated exclusively for the management of conditions associated with impaired copper metabolism:
- Wilson-Konovalov Disease: The primary indication for patients of all age groups (including children) who have documented intolerance to D-penicillamine (agranulocytosis, systemic lupus erythematosus, nephrotic syndrome, severe skin reactions).
- Resistance to First-line Therapy: Cases where standard treatment fails to provide adequate copper excretion or does not resolve the clinical manifestations of the disease.
- Maintenance Therapy: Long-term control of copper levels in the body after initial stabilization has been achieved.
Dosage and administration
Trientine therapy requires precise dose titration and regular monitoring of 24-hour urinary copper excretion (the target range is 0.5–1.0 mg of copper per day during treatment).
- Adult Regimen: The initial dose ranges from 750 mg to 1250 mg per day, divided into 2, 3, or 4 doses. If necessary, the dose may be gradually increased to a maximum of 2000 mg per day.
- Pediatric Regimen (under 12 years): Usually prescribed at 500 mg to 750 mg per day in divided doses. The maximum allowable dose is 1500 mg per day.
- Critical Administration Rules:
- The drug must be taken on an empty stomach: at least 1 hour before or 2 hours after meals.
- Capsules must be swallowed whole, without opening or chewing, and washed down only with plain water. Contact of the powder with the oral mucosa may cause local irritation.
- Interval with other drugs: Iron supplements, zinc, and antacids must be taken at least 2–3 hours apart, as they bind with trientine and neutralize its effect.
- Storage Conditions: Many formulations of trientine (e.g., Syprine) require refrigeration at 2–8°C.
- Hypersensitivity: Individual intolerance to trientine dihydrochloride or any of the capsule's excipients.
- Pregnancy and Lactation: Trientine is prescribed only when the expected benefit to the mother outweighs the risk to the fetus. Strict monitoring of copper levels is required (teratogenic effects can be caused by both copper excess and critical deficiency due to over-chelation). A dose reduction in the third trimester is recommended.
- Cystinuria and Rheumatoid Arthritis: The drug is not indicated for the treatment of these conditions (unlike penicillamine).
- Severe Renal Impairment: Requires dose adjustment as the drug and copper complexes are excreted by the kidneys.
Trientine is considered less toxic than sulfhydryl chelators; however, the following systemic complications are possible:
- Hematologic Disorders: The most significant risk is the development of sideroblastic anemia due to secondary iron deficiency (trientine can chelate iron during long-term use).
- Neurological Effects: A risk of paradoxical worsening of neurological symptoms at the start of therapy (associated with the rapid release of copper from tissue stores into the systemic circulation).
- Gastrointestinal Reactions: Epigastric pain, nausea, vomiting, heartburn; melaena (blood in stool) may occur in rare cases.
- Dermatologic and Immune Reactions: Skin rash, itching; very rarely, a lupus-like syndrome (systemic lupus erythematosus).
- Metabolic Disorders: Hypocupremia (excessive reduction in copper levels), which can lead to damage to the nervous system and bones.
